# Thiazide Diuretics

## Examples

- `hydrochlorothiazide`
- `chlorthalidone`
- `indapamide`
- `bendroflumethiazide`
- `metolazone` _(thiazide-like)_

## Mechanism of Action (MOA)

- Act on the **early distal convoluted tubule (DCT)**.
- **Inhibit Na⁺/Cl⁻ co-transporter (NCC)** on luminal membrane → ↓ Na⁺ and Cl⁻ reabsorption.
- Result: ↑ excretion of **Na⁺, Cl⁻, K⁺, and water**, but **↑ reabsorption of Ca²⁺**.
- ↓ plasma volume → ↓ cardiac output (initial) → compensatory ↓ peripheral resistance (sustained BP reduction).

![Thiazide Acting](/pharmacology/cvs/anti-hypertensives/diuretics/thiazide-diuretics-acting.jpg)

## Pharmacodynamics (Effects)

- **↓ Blood pressure** (initially due to volume loss, later due to vasodilation).
- **↑ Na⁺ and water excretion**, mild diuretic effect (less than loop diuretics).
- **↑ Ca²⁺ reabsorption** → ↓ urinary Ca²⁺ → beneficial in calcium stone disease.
- **Potentiates other anti-hypertensives** (esp. ACEIs, ARBs, β-blockers).

## Pharmacokinetics

| Property             | Notes                                                                                                    |
| :------------------- | :------------------------------------------------------------------------------------------------------- |
| **Absorption**       | Well absorbed orally.                                                                                    |
| **Onset / Duration** | Slow onset; long duration (12–24 h). `chlorthalidone` has a longer half-life than `hydrochlorothiazide`. |
| **Elimination**      | Excreted unchanged in urine. Ineffective if GFR < 30 mL/min (except `metolazone`).                       |

## Indications

- **Primary (essential) hypertension** — _first-line drug_ for mild–moderate hypertension.
- **Edema** due to heart failure, nephrotic syndrome, cirrhosis.
- **Nephrolithiasis (calcium stones)** — ↓ urinary calcium.
- **Nephrogenic diabetes insipidus** — paradoxically ↓ urine volume.
- **Adjunct in osteoporosis** (mild calcium retention).

## Adverse Effects

Mnemonic: **“Hyper-GLUC” + hypokalemia, hyponatremia**

| Effect                           | Mechanism                                            |
| :------------------------------- | :--------------------------------------------------- |
| **Hypokalemia**                  | ↑ Na⁺ delivery to distal tubule → ↑ K⁺ secretion     |
| **Hyponatremia**                 | Excessive Na⁺ loss with water retention              |
| **Hypomagnesemia**               | ↑ Mg²⁺ loss                                          |
| **Hypercalcemia**                | ↓ Ca²⁺ excretion                                     |
| **Hyperuricemia**                | Competes with uric acid secretion (→ gout)           |
| **Hyperglycemia**                | ↓ insulin release, ↓ glucose utilization             |
| **Hyperlipidemia**               | ↑ LDL and TG in early therapy                        |
| **Erectile dysfunction**         | Possibly due to volume depletion or vascular effects |
| **Sulfonamide hypersensitivity** | Rash, photosensitivity (sulfa derivatives)           |

## Cautions

- **Elderly** (risk of hyponatremia).
- **Gout** (may precipitate attacks).
- **Diabetes mellitus** (may raise glucose).
- **Patients on digoxin** — hypokalemia increases toxicity.
- **Concomitant lithium therapy** — may increase serum lithium levels.

## Contraindications

- **Severe renal impairment (GFR < 30 mL/min)** — ineffective.
- **Sulfonamide allergy** (relative).
- **Severe hepatic disease** — may worsen electrolyte imbalance.
- **Pregnancy (late stage)** — risk of volume depletion in fetus.
